Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.9115
+$0.0315 · +1.09%
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Regular session
$2.9115
+$0.0315 · +1.09%
Regular session · ET · Market data may be delayed.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Day range
Current $2.9115
52-week range
Current $2.9115
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
33
Expensive
Sentiment
61
Bullish
Risk
60
Elevated Risk
Momentum
44
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Day range
Current $2.9115
52-week range
Current $2.9115
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$11.33
289.15% upsidePrice history unavailable
High $13.00Average $11.33Low $10.00Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI8.38M0.00%2.3T USD0.03%$379.42-0.42%
iShares Russell 2000 ETFIWM3.84M0.00%78.56B USD0.19%$277.54-0.06%
Vanguard Extended Market ETFVXF2.4M0.00%95.4B USD0.05%$233.21-0.12%
Vanguard Russell 2000 ETFVTWO925.7K0.01%18B USD0.06%$112.09-0.11%
iShares Micro-Cap ETFIWC491.96K0.04%1.33B USD0.60%$182.72-0.35%
ALPS Medical Breakthroughs ETFSBIO330.34K0.18%188.26M USD0.50%$53.86-0.50%
Avantis U.S. Small Cap Equity ETFAVSC313.53K0.01%3.04B USD0.25%$69.965+0.48%
Simplify Propel Opportunities ETFSURI301.97K0.40%74.84M USD2.82%$17.01+0.95%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCALPS Medical Breakthroughs ETFSBIOAvantis U.S. Small Cap Equity ETFAVSCSimplify Propel Opportunities ETFSURIAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
